1.
Curr Oncol
; 16(5): 84-6, 2009 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19862366
RESUMO
Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil-based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to FOLFIRI and FOLFOX chemotherapy regimens who showed a dramatic and durable response to bevacizumab and FOLFIRI. We also review and discuss the available literature.
2.
JFORL J Fr Otorhinolaryngol Audiophonol Chir Maxillofac
; 22(1): 67-9, 1973 Jan.
Artigo
em Francês
| MEDLINE
| ID: mdl-4267456
3.
Ann Odontostomatol (Lyon)
; 23(2): 63-73, 1966.
Artigo
em Francês
| MEDLINE
| ID: mdl-5328429